Do Alzheimer’s Drugs Really Work? New Review Says Benefits Are ‘Trivial’—Here’s What Matters More
A major new systematic review is challenging the narrative around Alzheimer’s medications. Are drugs like lecanemab and donanemab truly changing outcomes—or offering only modest benefits? In this video, Dr. Mikhail Kogan (George Washington University Center for Integrative Medicine) breaks down the latest evidence, including a large meta-analysis of over 20,000 patients, and explains what it really means for patients, families, and clinicians. While newer anti-amyloid therapies may slow decline slightly, the overall clinical impact remains debated—especially when weighed against risks like brain swelling (ARIA), cost, and treatment burden. More importantly, we discuss what does move the needle: a comprehensive, root-cause approach to cognitive decline—addressing inflammation, metabolic health, toxins, sleep, and more.
Mikhail Kogan, MD
Integrative and Functional Medicine Physician | ReCODE Program | Chief Medical Officer